PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277791
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in
      Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.
PG  - 329-336
AB  - BACKGROUND: Hypoxia-inducible factors (HIFs) and prolyl hydroxylase domain (PHD) 
      proteins control cellular oxygen homeostasis and a wide range of other processes.
      MATERIALS AND METHODS: We immunohistochemically assessed the expression of
      HIF1alpha, HIF2alpha, PHD1, PHD2 and PHD3 in 115 cases of classical Hodgkin's
      lymphoma, all treated in the first line with doxorubicin, bleomycin, vinblastine 
      and darcabazine (ABVD) chemotherapy. RESULTS: In advanced-stage patients treated 
      with involved-field radiotherapy (IFRT), nuclear HIF1alpha expression in reactive
      cellular infiltrate predicted prolonged relapse-free survival (RFS) (p=0.026).
      Strong cytoplasmic PHD1 expression in Reed-Sternberg cells was associated with
      poor RFS among patients treated with IFRT and advanced-stage patients treated
      with ABVD and IFRT (p=0.0028 and p=0.0058, respectively). In Cox regression
      analysis, PHD1 was a more significant predictor of relapse (risk ratio=18.383;
      95% confidence interval(CI)=1.521-222.246; p=0.022) than the International
      Prognostic Score. CONCLUSION: HIF and PHD expression appear to be novel
      prognostic biomarkers in classical Hodgkin's lymphoma.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Bur, Hamid
AU  - Bur H
AD  - Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu
      University Hospital, Oulu, Finland.
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, Oulu,
      Finland.
FAU - Haapasaari, Kirsi-Maria
AU  - Haapasaari KM
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, Oulu,
      Finland.
AD  - Department of Pathology, Medical Research Center Oulu, Oulu University Hospital, 
      Oulu, Finland.
FAU - Turpeenniemi-Hujanen, Taina
AU  - Turpeenniemi-Hujanen T
AD  - Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu
      University Hospital, Oulu, Finland.
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, Oulu,
      Finland.
FAU - Kuittinen, Outi
AU  - Kuittinen O
AD  - Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu
      University Hospital, Oulu, Finland.
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, Oulu,
      Finland.
FAU - Auvinen, Paivi
AU  - Auvinen P
AD  - Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
AD  - Cancer Center, Institute of Clinical Medicine, University of Eastern Finland,
      Kuopio, Finland.
FAU - Marin, Katja
AU  - Marin K
AD  - Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
AD  - Cancer Center, Institute of Clinical Medicine, University of Eastern Finland,
      Kuopio, Finland.
FAU - Soini, Ylermi
AU  - Soini Y
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, Oulu,
      Finland.
AD  - Department of Pathology, Medical Research Center Oulu, Oulu University Hospital, 
      Oulu, Finland.
AD  - Cancer Center, Institute of Clinical Medicine, University of Eastern Finland,
      Kuopio, Finland.
AD  - Department of Pathology and Forensic Medicine, Institute of Clinical Medicine,
      University of Eastern Finland, Kuopio, Finland.
FAU - Karihtala, Peeter
AU  - Karihtala P
AD  - Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu
      University Hospital, Oulu, Finland [email protected]
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, Oulu,
      Finland.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (endothelial PAS domain-containing protein 1)
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - EC 1.14.11.- (Prolyl Hydroxylases)
RN  - EC 1.14.11.2 (EGLN1 protein, human)
RN  - EC 1.14.11.29 (EGLN2 protein, human)
RN  - EC 1.14.11.29 (EGLN3 protein, human)
RN  - EC 1.14.11.29 (Hypoxia-Inducible Factor-Proline Dioxygenases)
RN  - ABVD protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Basic Helix-Loop-Helix Transcription Factors/biosynthesis
MH  - Biomarkers, Tumor/*biosynthesis
MH  - Bleomycin/therapeutic use
MH  - Cell Hypoxia/physiology
MH  - Dacarbazine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - Hodgkin Disease/drug therapy/mortality/*pathology/*radiotherapy
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis
MH  - Hypoxia-Inducible Factor-Proline Dioxygenases/biosynthesis
MH  - Male
MH  - Middle Aged
MH  - Prolyl Hydroxylases/*biosynthesis
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vinblastine/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - *HIF
OT  - *Hodgkin's lymphoma
OT  - *Hypoxia
OT  - *PHD
OT  - *prognosis
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/17 00:00 [received]
PHST- 2017/11/06 00:00 [revised]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/329 [pii]
AID - 10.21873/anticanres.12226 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):329-336. doi: 10.21873/anticanres.12226.